Company / Depreciation & Amortization
Abbott Laboratories Depreciation & Amortization History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.5B
FY2023
5-year range
$1.1B / $1.5B
FY2019-FY2023
Trend
+24.8%
vs FY2022
Sector context
#8 of 141
Health Care
What the data says
Among 141 Health Care companies, Abbott Laboratories is in the bottom 6% for depreciation & amortization. Depreciation & Amortization has fluctuated over the past 7 years, ranging from $803M in FY2018 to $1.5B in FY2023.
Based on SEC 10-K filings.
$1.5B in FY2023 with a 5-year CAGR of +13.2%. Top quartile in the Health Care sector.
Increased from $1.1B to $1.5B over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +10.7%
- 5-Year CAGR
- +13.2%
- 10-Year CAGR
- -
Sector benchmark
+332.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +13.2%, indicating consistent growth.
- In FY2023, depreciation & amortization increased 24.8% year-over-year.
- Ranks #8 out of 141 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2018.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $1.5B | +24.8% |
| FY2022 | $1.2B | +10.9% |
| FY2021 | $1.1B | -2.0% |
| FY2020 | $1.1B | - |
| FY2019 | - | - |
| FY2018 | $803.0M | -7.8% |
| FY2017 | $871.0M | -5.1% |
| FY2016 | $918.0M | -1.1% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026